Please login to the form below
Bayer pays an initial $2bn for gene therapy firm AskBio
Acquisition will expand Bayers’s pipeline with preclinical/clinical candidates
Both AZ and J&J set to resume US COVID-19 vaccine trials
Both companies paused their trials after separate participant illness events
AZ’s COVID-19 vaccine shows promise in younger and older adults
Company said vaccine produces similar immune response in younger and older adults
FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients
Antiviral drug initially scored emergency use authorisation in May
Vaccine developers call on FDA to offer clarity on COVID-19 trials
Comments from J&J and Pfizer made before FDA advisory committee meeting yesterday
Moderna completes enrolment of phase 3 COVID-19 vaccine trial
Late-stage study hits 30,000 participant target
Purdue to pay over $8bn to settle opioid-related criminal claims
Claims relate to Purdue's involvement in fuelling the opioid addiction crisis
Roche and Atea link up for oral COVID-19 drug; UK to test coronavirus vaccine T cell responses
New developments for COVID-19 treatments and vaccines
AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death
Reports indicate that the death occurred in the placebo group
Q&A: Caroline Gosling
PME interviews Rubica's Director of Culture & Engagement
-
Q&A: Isabel GibsonPME interviews W2O ISO's Managing Director
-
Q&A: Kate Callan
-
Independent consultant will review Lilly’s COVID-19 plant issuesCOVID-19 antibody trial was paused last week due to safety issue
-
AZ’s US-based COVID-19 vaccine trial could restart this weekSources briefed on the matter disclosed possible timeline to Reuters
-
Roche and Prothena set to advance Parkinson’s disease candidate into phase 2bDrug moves into late-stage testing despite failing to hit primary endpoint in previous trial
-
Moderna’s chief exec expects to have COVID-19 vaccine data in NovemberIf data is promising, company could seek emergency use authorisation in the US in December
-
UK government invests in human challenge trials for COVID-19The trials could begin in 2021 if approved by regulators
-
Novartis scores CHMP backing for cholesterol drug Leqvio Potential first-in-class treatment moves closer to EU approval
-
Galapagos mid-stage trial failure raises concerns for Gilead deal Investigational osteoarthritis treatment misses primary endpoint in phase 2 study
Latest appointments
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm Perlmutter is set to join the board of AI drug discovery biotech Insitro
-
90TEN bolsters senior management team Agency establishes new role of head of behavioural science
-
Evoke KYNE promotes Dante DelVecchio to senior VP DelVecchio takes on the role after ten years at Evoke KYNE
-
McCann Health North America appoints Jim Joseph as president Joseph will oversee all North American advertising and promotion agencies in the US and Canada
-
Ex-J&J exec Denice Torres joins bluebird bio’s boardTorres brings over 25 years of executive management experience to the role
COVID-19 Updates and Daily News
Featured jobs
- FDA sets November date for expert panel review of Biogen’s aducanumab
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b
- Vaccine developers call on FDA to offer clarity on COVID-19 trials
- How will the events and exhibitions industry change post-Coronavirus?
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- Exploring the potential of eosinophils
- GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
- Eliminating pharmaceutical rebates, is this déjà vu?
- By Andrew Parece and Matthew Majewski...
- Patients are ready to embrace decentralised clinical trials, are you?
- Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Quick links
Infographics
